The Evolving Role of CAR T-Cell Therapy in Treating Multiple Myeloma
Introduction
Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow. Despite advances in treatment, many patients with multiple myeloma experience relapse or become refractory to chemotherapy. In recent years, chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising new treatment option for these patients.
Expert Insights on CAR T-Cell Therapy
A recent Training Academy hosted by CancerNetwork® brought together experts in multiple myeloma to discuss the evolving role of CAR T-cell therapy in treating the disease. Here are some key takeaways from the discussion:
Latest Findings from Clinical Trials
The panelists highlighted the latest findings from clinical trials involving CAR T-cell therapy for multiple myeloma. Studies have shown that these therapies can be effective in treating relapsed or refractory disease, with response rates ranging from 70% to 90%. However, there are still challenges associated with CAR T-cell therapy, including toxicity and the development of resistance over time.
Recent FDA Approvals
The experts also discussed recent FDA approvals of CAR T-cell therapies for multiple myeloma. In 2023, the agency approved idecabtagene vicleucel (Abecma) for the treatment of adults with relapsed or refractory disease. In 2024, the FDA approved the use of ciltacabtagene autoleucel (cilta-cel) for the same indication. These approvals represent significant milestones in the development of CAR T-cell therapy for multiple myeloma.
Other Developments
The panelists also highlighted other developments that could change the multiple myeloma treatment paradigm. For example, there is ongoing research into the use of CAR T-cell therapy in combination with other drugs, such as checkpoint inhibitors and immunomodulators. There is also research being done to identify biomarkers that can predict which patients are most likely to respond to CAR T-cell therapy.
Other Articles in This Issue
Here are some other articles in this issue of the online healthcare magazine that are related to multiple myeloma:
Liso-Cel Approval in Mantle Cell Lymphoma
Michael Wang, MD, discusses the recent approval of liso-cel for mantle cell lymphoma and the TRANSCEND trial.
Research on Agents Like Ciltacabtagene Autoleucel
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Case Study: Neoadjuvant Capecitabine and Temozolomide
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Data Updates in Real-World Newly Diagnosed Multiple Myeloma Practices
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Highlights from the 2024 ASCO Annual Meeting
Julie M. Vose, MD, MBA, looks back at the 2024 ASCO Annual Meeting and highlights key presentations.
Originally Post From https://www.cancernetwork.com/view/leveraging-car-t-cell-therapy-advancements-in-r-r-multiple-myeloma
Read more about this topic at
From bench to bedside: the history and progress of CAR T …
the history and progress of CAR T cell therapy – PMC
